Likang gets trial ok for China’s first personalized cancer vaccine
Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted…
Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted…
As February 28 is Rare Disease Day, we have three guests on the podcast today…
INOVIO Pharmaceuticals has announced positive preliminary results from the second cohort of its phase 1/2…
T-cells are central in the protection against infections and cancer. With the help of TCRs…
Scancell Holdings plc, which develops novel immunotherapies for the treatment of cancer and infectious disease,…
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The…
A research team from the LKS Faculty of Medicine, the University of Hong Kong (HKUMed)…
Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101,…
Legend Biotech Corporation has announced that China’s National Medical Products Administration (NMPA) has formally accepted…
The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial…
PDC*line Pharma, a clinical stage biotech company has announced the first immunological results of its…
Laevoroc Oncology, a privately-owned, Swiss oncology development company, has announced the publication of key preclinical…